Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 10/20 | 0.60 |
| ▸ | NPC1 | O15118 | 9/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | PKM | P14618 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | GFER | P55789 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | USP2 | O75604 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL859776 | 0.98 | RAB9A (0.58) | RAB9ANPC1SMN1; SMN2LMNAKDM4E | |
| SCHEMBL1059693 | 0.84 | RAB9A (0.64) | RAB9ANPC1SMN1; SMN2LMNAKDM4E | |
| SCHEMBL31248989 | 0.83 | SMN1; SMN2 (0.65) | RAB9ANPC1SMN1; SMN2LMNAKDM4E | |
| SCHEMBL3746825 | 0.83 | SMN1; SMN2 (0.65) | RAB9ANPC1SMN1; SMN2LMNAKDM4E | |
| SCHEMBL30037937 | 0.82 | RAB9A (0.62) | RAB9ANPC1SMN1; SMN2LMNAKDM4E | |
| SCHEMBL757031 | 0.82 | RAB9A (0.62) | RAB9ANPC1SMN1; SMN2LMNAKDM4E | |
| SCHEMBL243922 | 0.81 | LMNA (0.61) | RAB9ANPC1SMN1; SMN2LMNAKDM4E | |
| SCHEMBL104281 | 0.81 | HDAC6 (0.61) | RAB9ANPC1SMN1; SMN2LMNAKDM4E | |
| SCHEMBL14050118 | 0.81 | MAPT (0.76) | RAB9ANPC1SMN1; SMN2LMNAKDM4E | |
| SCHEMBL2929122 | 0.81 | MAPT (0.66) | RAB9ANPC1SMN1; SMN2LMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3455224-B1 | SUBSTITUTED 5,6,7,8-TETRAHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRIDINE-3(2H)-ONES AND 2,5,6,7-TETRAHYDRO-3H-PYRROLO[2,1-C][1,2,4]TRIAZOL-3-ONES, AND USE THEREOF | BAYER AG (DE) | 2024-03-27 | — | — | EP | disclosed |
| US-11858918-B2 | GLP-1R modulating compounds | GILEAD SCIENCES, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-11858918-B2 | GLP-1R modulating compounds | GILEAD SCIENCES, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| CN-109476658-B | Substituted 5,6,7, 8-tetrahydro [1,2,4] triazolo [4,3-a ] pyridin-3 (2H) -ones and 2,5,6, 7-tetrahydro-3H-pyrrolo [2,1-c ] [1,2,4] triazol-3-ones and uses thereof | 拜耳公司 | 2021-08-10 | — | — | CN | disclosed |
| EP-3523277-B1 | SUBSTITUTED PYRROLIDINES AS CFTR MODULATORS | ABBVIE OVERSEAS SARL (LU) | 2021-06-30 | — | — | EP | disclosed |
| US-10722501-B2 | Substituted 5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-A]pyridine-3(2H)-ones and 2,5,6,7-tetrahydro-3H-pyrrolo[2,1-C][1,2,4]triazol-3-ones, and use thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2020-07-28 | — | — | US | disclosed |
| US-20190315687-A1 | Substituted Pyrrolidines and Methods of Use | ABBVIE S.Á.R.L. (LU) | 2019-10-17 | — | — | US | disclosed |
| EP-2432776-B1 | METHYL SULFANYL PYRIMIDINES USEFUL AS ANTIINFLAMMATORIES, ANALGESICS, AND ANTIEPILEPTICS | UNIV LAVAL (CA) | 2019-09-11 | — | — | EP | disclosed |
| US-10399940-B2 | Substituted pyrrolidines and methods of use | ABBVIE S.Á.R.L. (LU) | 2019-09-03 | — | — | US | disclosed |
| US-20190160048-A1 | SUBSTITUTED 5,6,7,8-TETRAHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRIDINE-3(2H)-ONES AND 2,5,6,7-TETRAHYDRO-3H-PYRROLO[2,1-C][1,2,4]TRIAZOL-3-ONES, AND USE THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2019-05-30 | — | — | US | disclosed |
| US-20090192138-A1 | COMPOUNDS | BAESCHLIN DANIEL KASPAR | 2009-07-30 | — | — | US | disclosed |
| EP-2073806-A2 | USE OF SPIRO-OXINDOLE COMPOUNDS AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2009-07-01 | — | — | EP | disclosed |
| EP-1966215-A1 | CONDENSED HETEROCYCLIC COMPOUNDS USEFUL AS DPP-IV INHIBITORS | Novartis AG (CH) | 2008-09-10 | — | — | EP | disclosed |
| WO-2008060789-A2 | USE OF SPIRO-OXINDOLE COMPOUNDS AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2008-05-22 | — | — | WO | disclosed |
| EP-1888595-A2 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2008-02-20 | — | — | EP | disclosed |
| WO-2007071738-A1 | CONDENSED HETEROCYCLIC COMPOUNDS USEFUL AS DPP-IV INHIBITORS | NOVARTIS AG (CH) | 2007-06-28 | — | — | WO | disclosed |
| US-20060252812-A1 | Spiro-oxindole compounds and their uses as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2006-11-09 | — | — | US | disclosed |
| WO-2006110917-A2 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2006-10-19 | — | — | WO | disclosed |
| US-5159085-A | Antiinflammatory, antiallergens, cytoprotective agents | AMERICAN HOME PRODUCTS CORPORATION (US) | 1992-10-27 | — | — | US | disclosed |
| US-5021576-A | Antiinflammatory, antiarthritic, hypotensive, anticarcinogenic agents | AMERICAN HOME PRODUCTS CORPORATION (US) | 1991-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190315687-A1 | Substituted Pyrrolidines and Methods of Use | CFTR, PKD1, PKD2 | RAB9A 867/4885NPC1 1247/4885SMN1; SMN2 3669/4885 |
| US-20190160048-A1 | SUBSTITUTED 5,6,7,8-TETRAHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRIDINE-3(2H)-ONES AND 2,5,6,7-TETRAHYDRO-3H-PYRROLO[2,1-C][1,2,4]TRIAZOL-3-ONES, AND USE THEREOF | THPO, PTGIS, PYCR1 | RAB9A 4108/4885NPC1 3029/4885SMN1; SMN2 3406/4885 |
| US-10399940-B2 | Substituted pyrrolidines and methods of use | CFTR, PKD1, PKD2 | RAB9A 867/4885NPC1 1247/4885SMN1; SMN2 3669/4885 |
| US-20090192138-A1 | COMPOUNDS | DPP4, DPP3, DPP8 | RAB9A 3148/4885NPC1 728/4885SMN1; SMN2 2888/4885 |
| US-11858918-B2 | GLP-1R modulating compounds | GLP1R, GIPR, GPR119 | RAB9A 478/4885NPC1 1188/4885SMN1; SMN2 1956/4885 |
| US-10722501-B2 | Substituted 5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-A]pyridine-3(2H)-ones and 2,5,6,7-tetrahydro-3H-pyrrolo[2,1-C][1,2,4]triazol-3-ones, and use thereof | PTGIS, CYP11B2, IL1B | RAB9A 4159/4885NPC1 2794/4885SMN1; SMN2 3643/4885 |
| US-20060252812-A1 | Spiro-oxindole compounds and their uses as therapeutic agents | OPRK1, OPRD1, SCN3A | RAB9A 757/4885NPC1 1791/4885SMN1; SMN2 902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.